About Echo Therapeutics (NASDAQ:ECTE)
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NASDAQ:ECTE
- CUSIP: N/A
- Web: www.echotx.com
- 50 Day Moving Avg: $0.03
- 200 Day Moving Avg: $0.05
- 52 Week Range: $0.01 - $0.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.01
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.55) per share
- Price / Book: -0.03
- EBITDA: ($5,180,000.00)
- Return on Assets: 216.11%
- Average Volume: 15,962 shs.
- Beta: 1.14
- Short Ratio: 3.4
Frequently Asked Questions for Echo Therapeutics (NASDAQ:ECTE)
What is Echo Therapeutics' stock symbol?
Echo Therapeutics trades on the NASDAQ under the ticker symbol "ECTE."
How were Echo Therapeutics' earnings last quarter?
Echo Therapeutics Inc (NASDAQ:ECTE) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.82) earnings per share for the quarter. During the same period in the prior year, the firm earned ($0.97) earnings per share. View Echo Therapeutics' Earnings History.
When will Echo Therapeutics make its next earnings announcement?
Who are some of Echo Therapeutics' key competitors?
Some companies that are related to Echo Therapeutics include Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Roche Holding (RHHBY), Novartis AG (NVS), Merck & Company (MRK), AbbVie (ABBV), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bayer AG (BAYRY), Medtronic PLC (MDT), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Celgene Corporation (CELG), Eli Lilly and Company (LLY) and Astrazeneca PLC (AZN).
Who are Echo Therapeutics' key executives?
Echo Therapeutics' management team includes the folowing people:
- Alan W. Schoenbart CPA, Chief Executive Officer, Chief Financial Officer, Secretary, Director
How do I buy Echo Therapeutics stock?
Shares of Echo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Echo Therapeutics' stock price today?
MarketBeat Community Rating for Echo Therapeutics (NASDAQ ECTE)MarketBeat's community ratings are surveys of what our community members think about Echo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Echo Therapeutics stock can currently be purchased for approximately $0.02.
Consensus Ratings for Echo Therapeutics (NASDAQ:ECTE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Echo Therapeutics (NASDAQ:ECTE)
Analysts' Ratings History for Echo Therapeutics (NASDAQ:ECTE)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Echo Therapeutics (NASDAQ:ECTE)Earnings History by Quarter for Echo Therapeutics (NASDAQ ECTE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017|| || || || || || || || |
|8/14/2014||Q214||($0.23)||($0.31)||$22.56 million||$19.10 million||View||N/A|
|5/9/2014||Q114||($0.26)||($0.23)||$0.02 million||$0.02 million||View||N/A|
|3/27/2014||Q413||($0.36)||($0.35)||$0.02 million||($0.04) million||View||N/A|
|8/8/2013||Q2 2013||($0.81)||($0.51)||$10.00 million||$22.56 million||View||N/A|
|5/10/2013||Q1 2013||($0.10)||($0.13)||$0.01 million||View||N/A|
Earnings Estimates for Echo Therapeutics (NASDAQ:ECTE)
Current Year EPS Consensus Estimate: $-1.190 EPS
Next Year EPS Consensus Estimate: $-1.700 EPS
Dividend History for Echo Therapeutics (NASDAQ:ECTE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Echo Therapeutics (NASDAQ:ECTE)Insider Trades by Quarter for Echo Therapeutics (NASDAQ:ECTE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/20/2015||Alan Wayne Schoenbart||CFO||Buy||2,500||$1.44||$3,600.00|| |
|5/20/2015||Scott Wayne Hollander||CEO||Buy||8,000||$1.48||$11,840.00|| |
|6/30/2014||Mark Nordlicht||Major Shareholder||Buy||65,739||$2.20||$144,625.80|| |
|6/26/2014||Mark Nordlicht||Major Shareholder||Buy||17,300||$2.20||$38,060.00|| |
|6/24/2014||Mark Nordlicht||Major Shareholder||Buy||16,961||$2.20||$37,314.20|| |
|12/10/2013||Mark Nordlicht||major shareholder||Buy||69,569||$2.75||$191,314.75|| |
|3/22/2013||Robert F Doman||Director||Buy||15,000||$0.80||$12,000.00|| |
|3/21/2013||William Grieco||Director||Buy||30,000||$0.76||$22,800.00|| |
|8/23/2012||James Francis Smith||Director||Buy||20,000||$1.47||$29,400.00|| |
Headline Trends for Echo Therapeutics (NASDAQ:ECTE)
Latest Headlines for Echo Therapeutics (NASDAQ:ECTE)
|/C O R R E C T I O N -- Manchester Management LLC/|
finance.yahoo.com - October 5 at 9:59 AM
|Echo Therapeutics Announces Federal Court's Denial Of Preliminary Injunction And Lifting Of Temporary Restraining Order|
finance.yahoo.com - October 5 at 9:59 AM
|Echo Therapeutics Announces Dismissal of Federal Court Action|
finance.yahoo.com - October 5 at 9:59 AM
|Echo Therapeutics (NASDAQ:ECTE) vs. Tonix Pharmaceuticals Holding Corp. (TNXP) Head-To-Head Comparison|
www.americanbankingnews.com - July 23 at 10:20 AM
|Tonix Pharmaceuticals Holding Corp. (TNXP) versus Echo Therapeutics (ECTE) Head-To-Head Analysis|
www.americanbankingnews.com - July 22 at 8:02 AM
|Analyzing Echo Therapeutics (ECTE) & Tonix Pharmaceuticals Holding Corp. (TNXP)|
www.americanbankingnews.com - July 20 at 10:16 PM
|Financial Contrast: Echo Therapeutics (ECTE) & Tonix Pharmaceuticals Holding Corp. (TNXP)|
www.americanbankingnews.com - July 16 at 2:20 PM
|Reviewing Echo Therapeutics (ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)|
www.americanbankingnews.com - July 11 at 7:36 AM
|Head to Head Contrast: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Echo Therapeutics (ECTE)|
www.americanbankingnews.com - July 7 at 8:07 AM
|Critical Review: Echo Therapeutics (NASDAQ:ECTE) and Tonix Pharmaceuticals Holding Corp. (TNXP)|
www.americanbankingnews.com - July 6 at 4:26 PM
|Financial Analysis: Tonix Pharmaceuticals Holding Corp. (TNXP) and Echo Therapeutics (ECTE)|
www.americanbankingnews.com - July 6 at 7:42 AM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - December 14 at 5:53 PM
|2:28 pm Echo Therapeutics announces they were informed by BDO USA that BDO was resigning as the co's independent registered public accounting firm|
us.rd.yahoo.com - December 1 at 10:00 PM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-B|
biz.yahoo.com - October 19 at 5:07 PM
|EARNINGS SUMMARY: Details of Echo Therapeutics, Inc Q2 Earnings Report|
www.rttnews.com - August 13 at 4:42 PM
|Echo Fails The Test, OREX To Effect Reverse Split, PFE's S-TRAC Study Hits Goal|
www.rttnews.com - July 11 at 9:34 AM
|Echo Therapeutics Gets Fresh Patent For Non-Invasive Sensing Technology|
feeds.benzinga.com - June 22 at 9:30 AM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia|
biz.yahoo.com - June 3 at 10:13 AM
|Echo Therapeutics Says It's In Final Stage Of Clinical Research Organization Selection|
feeds.benzinga.com - June 2 at 10:09 AM
|Echo Therapeutics, Inc. Announces First Quarter 2016 Financial Results - PR Newswire (press release)|
www.prnewswire.com - May 20 at 3:36 PM
|EARNINGS SUMMARY: Details of Echo Therapeutics, Inc Q1 Earnings Report|
www.rttnews.com - May 20 at 3:36 PM
|Echo Therapeutics Announces Successful Software Transfer to its Strategic Partner, MTIA - PR Newswire (press release)|
www.prnewswire.com - May 17 at 3:37 PM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - April 14 at 3:38 PM
|ECHO THERAPEUTICS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 30 at 4:59 PM
|Echo Therapeutics Says Nasdaq Granted Request to Remain Listed|
feeds.benzinga.com - March 10 at 1:17 PM
|Echo Therapeutics, Inc. (ECTE)|
biz.yahoo.com - February 25 at 8:55 PM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia|
biz.yahoo.com - February 3 at 6:07 AM
|ECHO THERAPEUTICS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rights o|
biz.yahoo.com - September 30 at 1:30 PM
Echo Therapeutics (ECTE) Chart for Friday, October, 20, 2017